Sign In
Buy SBIO
$51.02
+0.710 (+1.41%)
At Close: Jun 03, 2026
Sabio Holdings Inc. (SBIO:CA) Q1 2026 Earnings Call Transcript
12:57pm, Tuesday, 26'th May 2026
Sabio Holdings Inc. (SBIO:CA) Q1 2026 Earnings Call Transcript
Creator TV Sports™' Creator Poker Championship to Premiere on CBS Sports Network
07:00am, Tuesday, 12'th May 2026
Produced series marks the Creator Poker Championship's transition from livestream to television. TORONTO, May 12, 2026 /PRNewswire/ -- Sabio Holdings (TSXV: SBIO) (OTCQB: SABOF) (the "Company" or "Sab
Sabio Holdings Inc. (SBIO:CA) Q4 2025 Earnings Call Transcript
03:41pm, Friday, 01'st May 2026
Sabio Holdings Inc. (SBIO:CA) Q4 2025 Earnings Call Transcript
Last Week's Top 5 Articles Highlight Areas of Interest, Concern
11:33am, Tuesday, 28'th Apr 2026
The leading articles for last week ran the gamut in terms of topics, but suggest investors are still worried about inflation and remain interested in biotech, nuclear energy, and derivatives strategie
SBIO: Leaning Into Drug Discovery And Medical Breakthroughs
10:41am, Tuesday, 28'th Apr 2026
ALPS Medical Breakthroughs ETF (SBIO) targets late-stage clinical biotech firms poised for FDA approval or acquisition, offering high-risk, high-reward exposure. SBIO surged 91% over the past year, ou
This Biotech ETF's Hot Start Can Continue
12:29pm, Monday, 20'th Apr 2026
Broader healthcare ETFs aren't doing much to appease investors this year, but biotech funds are warding off that weakness. Just look at the ALPS Medical Breakthroughs ETF (SBIO).
UFO Takes Flight: Agility and Assets Converge in the Final Frontier
09:28am, Monday, 20'th Apr 2026
While some investment themes have struggled to maintain their trajectory, the space economy has proven it has the fundamental fuel to reach escape velocity. This momentum is being met with a strategic
Biotech M&A Spree Helps Lead SBIO to March Gains
03:28pm, Wednesday, 08'th Apr 2026
A surge in biotech M&A activity drove sharp gains across holdings in the ALPS Medical Breakthroughs ETF (SBIO) during March, with two of the fund's holdings becoming acquisition targets in deals worth
Creator TV Launches "Creator Pickleball Tour" at VidCon Anaheim in Partnership with Viewws
07:00am, Tuesday, 07'th Apr 2026
Three-day fan activation and televised creator tournament introduces a new live programming format under Creator TV Sports TORONTO, April 7, 2026 /PRNewswire/ -- Sabio Holdings (TSXV: SBIO) (OTCQB: S
ETF Winners & Losers of Q1 2026
12:00pm, Thursday, 02'nd Apr 2026
Iran war reshaped Q1 markets: energy, shipping & lithium ETFs surged while tech and airlines lagged as inflation fears and oil shocks rattled sentiment.
Creator TV® Announces 2026 Sports Programming under Studio Label, Creator TV Sports
07:00am, Thursday, 02'nd Apr 2026
TORONTO, April 2, 2026 /PRNewswire/ -- Sabio Holdings (TSXV: SBIO) (OTCQB: SABOF) (the "Company" or "Sabio"), a Los Angeles-based ad-tech company helping top global brands reach, engage, and validate
Creator TV® and Convergence Announce Partnership to Bring Creator-Led Programming to Television
07:00am, Wednesday, 25'th Mar 2026
TORONTO, March 25, 2026 /PRNewswire/ -- Sabio Holdings (TSXV: SBIO) (OTCQB: SABOF) ("Sabio" or the "Company") announced today that its owned-and-operated network, Creator TV® has entered a partnershi
Creator Television Launches "Made By Her" Programming for Women's History Month
07:00am, Monday, 02'nd Mar 2026
TORONTO, March 2, 2026 /PRNewswire/ -- Sabio Holdings (TSXV: SBIO) (OTCQB: SABOF) ("Sabio" or the "Company") today announced special month-long programming in celebration of Women's History Month on
This Biotech ETF Is a Catalyst-Rich Story
09:04pm, Thursday, 19'th Feb 2026
Biotechnology stocks and the related ETFs bounced back in significant fashion last year. There's been some cooling of that trend to start 2026, but that could be just the opportunity some investors ha
Biotech M&A Wave Positions SBIO for Growth
03:04pm, Thursday, 29'th Jan 2026
The biotech M&A market is heating up as pharmaceutical companies confront a looming patent cliff that will strip $200 billion to $250 billion in branded medicine sales by 2032, according to an ING rep
